As seen in ALK-rearranged NSCLC, the adoption of next-generation TKIs in the first-line setting shifts the resistance landscape toward fewer on-target events and a greater proportion of off-target mechanisms, including histologic transformation [64]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.